G1 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

G1 Therapeutics

28/02/2024 16:57

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 21 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -73 cents.  The mean expectation of six analysts
for the quarter was for a loss of 28 cents per share. Wall
Street expected results to range from -30 cents to -22 cents per
share.
    * Revenue rose 45.1% to $14.87 million from a year ago;
analysts
expected $13.07 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 21 cents​.
    * The company reported a quarterly loss of $10.88 million.
    * G1 Therapeutics Inc shares had fallen by 21.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for G1 Therapeutics
Inc is $8.50 
This summary was machine generated from LSEG data February 28 at
04:57 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.28          -0.21          Beat
 Sep. 30 2023      -0.33          -0.35          Missed
 Jun. 30 2023      -0.22          0.14           Beat
 Mar. 31 2023      -0.64          -0.53          Beat